CD19-directed chimeric antigen receptor T (CD19 CAR-T) cell is a new modality for the treatment of B-ALL, B-cell lymphoma and chronic lymphocytic leukemia [3–5]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.